Skip to main content
. 2021 Jan 9;10(1):6. doi: 10.1038/s41389-020-00301-y

Fig. 1. Ovarian cancer patients with low FAM83B expression had poor clinic outcome.

Fig. 1

a Kaplan–Meier plots indicate the progression-free survival, overall survival and post progression survival for ovarian cancer patients categorized by FAM83B expression. P-value is determined by log-rank test. b GSEA analysis of the relationship between FAM83B level and cisplatin resistance. c Q-PCR and western blot analysis of FAM83B expression in ovarian cancer tissues with cisplatin resistance and cisplatin response. *P < 0.05. Error bars in panels are defined as s.d.